Tuesday, Feb 11 2025 | Time 10:53 Hrs(IST)
image
Business Economy


Laurus Labs net profit jumps 300 pc to Rs 92 crore in Q3FY25

Hyderabad, Jan 24 (UNI) Laurus Labs Ltd., a leading research and development-driven pharmaceutical and biotech company in India, on Friday reported a net profit of Rs 92 crore in Q3FY25, a 300 percent increase from Rs 23 crores in the previous year.
Revenue from operations rose 18 percent to Rs 1,415 crore during the quarter as compared to Rs 1,195 crore in the corresponding period in the previous year, Hyderabad-based pharma company said in a release here.
However, for the nine months in FY25, the net profit rose 47 percent to Rs 125 crore as against Rs 85 crore in 9MFY24 while the revenues increased 6 percent to Rs 3,834 crore compared to the year-ago period.
Commenting on the company’s performance, Dr. Satyanarayana Chava, Founder & Chief Executive Officer said “The quarter witnessed robust growth in the CDMO and FDF division, partially offset by soft API performance. Healthy commercial execution is our top priority and our performance is well on track with revenues accelerating in Q4”.
Based on our continued progress across diverse portfolio and pipeline projects I remain confident about our long-term future, and I acknowledge the focus and commitment of our team in making Laurus better positioned to deliver value to all stakeholder in coming years, he added.
V V Ravi Kumar, Executive Director & Chief Financial Officer commented; “We are pleased to report healthy progress for the quarter; we delivered ₹ 1,415 Cr in revenues, strong growth of 18 percent, and ₹ 285 crore EBITDA grew by 56 percent, resulting in 20.1 percent margin. Gross margins remained healthy at 56.9 percent due to favorable CDMO mix and process optimization measures. The fundamentals of our business remain healthy, driven by order book position and continued progress in CDMO projects”.
Our 9M performance remained on track, with revenues reaching ₹ 3,834 crore, representing 6 percent growth and EBITDA stood at ₹ 638 crore, marking a growth of 18 percent. We reaffirm our Full-year growth outlook, driven by scheduled CDMO project deliveries. Our capital allocation strategy remains unchanged, prioritizing investments into high value CMO/CDMO opportunities to drive near and long-term growth, he added.
UNI KNR BD
More News

Shrijee Lifestyle to Unveil Sustainable and Festive Collections at Bharat Tex 2025

10 Feb 2025 | 3:36 PM

Shrijee Lifestyle to Unveil Sustainable and Festive Collections at Bharat Tex 2025

see more..

Shrijee Lifestyle to Unveil Sustainable and Festive Collections at Bharat Tex 2025

10 Feb 2025 | 3:36 PM

Shrijee Lifestyle to Unveil Sustainable and Festive Collections at Bharat Tex 2025

see more..

Bangur Cement launches new premium product Bangur Marble for Solid Bright Homes

10 Feb 2025 | 8:46 PM

Kolkata, Feb 10 (UNI) Shree Cement has launched its premium product, Bangur Marble Cement under its master brand Bangur Cement.

see more..

Saregama revenues grows 100 pc at Rs 4834 in Q3

10 Feb 2025 | 8:03 PM

Mumbai Feb 10 (UNI) * Saregama, a RPSG Group company, announced its financial results for the Quarter and Nine Months Ended December 31, 2024 and reported the revenue from operation at Rs.4834 Mn grew 100 percent on Q-o-Q basis and 137 pc on Y-o-Y basis, courtesy revenue from Event segment which is Rs.2789 Mn in Q3FY25 as against Rs.100 Mn in corresponding quarter last year.

see more..

Maha Defence and Aerospace VF exits from two portfolio companies realising Rs 73 61 cr

10 Feb 2025 | 7:16 PM

New Delhi, Feb 10 (UNI) The Maharashtra Defence and Aerospace Venture Fund (MDAVF) on Monday said that it has successfully exited from two of its portfolio companies -- Cyronics Innovation Labs Pvt Ltd and JSR Dynamics Pvt Ltd realising Rs 14.46 crore and Rs 59.15 crore respectively.

see more..
image